Article
Targeting LAMP2 synergizes with gemcitabine to inhibit bladder cancer progression via modulating STING degradation and regulating macrophage phenotypes.
Apoptosis : an international journal on programmed cell death - 23 Sept 2026
Lv Yue, Yin Qiang, Li Wuheng, Deng Leihong, Liu Jiasheng, Lv Haolong, Zhang Peng, Qiu Yihang, Guo Difeng, Tao Rui, Gan Xiuguo, Xu Fanghua, Liu Zan, Wang Yongquan
Abstract excerpt
Bladder cancer (BLCA) is an aggressive malignancy characterized by metastasis and drug resistance, creating an urgent demand for novel therapeutic targets. The lysosomal protein LAMP2 acts as a key oncogenic driver in BLCA and modulates the degradation of STING. As reported in prior studies, mechanistically, p62-mediated macroautophagy and HSC70-dependent chaperone-mediated autophagy (CMA) facilitate STING...
Read the complete abstract on PubMedTopics
- Humans
- Gemcitabine
- Lysosomal-Associated Membrane Protein 2
- Animals
- Urinary Bladder Neoplasms